$2.43 Billion is the total value of Deep Track Capital, LP's 58 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RETA | Exit | REATA PHARMACEUTICALS INCcall | $0 | – | -12,600 | -100.0% | -0.02% | – |
| HOOK | Exit | HOOKIPA PHARMA INC | $0 | – | -1,240,369 | -100.0% | -0.04% | – |
| MGTA | Exit | MAGENTA THERAPEUTICS INC | $0 | – | -3,000,000 | -100.0% | -0.05% | – |
| AUPH | Exit | AURINIA PHARMACEUTICALS INC | $0 | – | -324,238 | -100.0% | -0.06% | – |
| Exit | THIRD HARMONIC BIO INC | $0 | – | -445,572 | -100.0% | -0.08% | – | |
| ASMB | Exit | ASSEMBLY BIOSCIENCES INC | $0 | – | -1,833,437 | -100.0% | -0.10% | – |
| FULC | Exit | FULCRUM THERAPEUTICS INC | $0 | – | -768,607 | -100.0% | -0.24% | – |
| VKTX | Exit | VIKING THERAPEUTICS INC | $0 | – | -610,083 | -100.0% | -0.24% | – |
| RNA | Exit | AVIDITY BIOSCIENCES INC | $0 | – | -300,000 | -100.0% | -0.28% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -871,493 | -100.0% | -0.40% | – |
| SNDX | Exit | SYNDAX PHARMACEUTICALS INC | $0 | – | -500,000 | -100.0% | -0.53% | – |
| CRNX | Exit | CRINETICS PHARMACEUTICALS IN | $0 | – | -1,048,829 | -100.0% | -0.81% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INC | $0 | – | -189,800 | -100.0% | -0.82% | – |
| ESPR | Exit | ESPERION THERAPEUTICS INC NE | $0 | – | -4,000,000 | -100.0% | -1.05% | – |
| ASND | Exit | ASCENDIS PHARMA A/Scall | $0 | – | -249,300 | -100.0% | -1.28% | – |
| ALBO | Exit | ALBIREO PHARMA INC | $0 | – | -1,704,000 | -100.0% | -1.55% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB Lput | $0 | – | -500,000 | -100.0% | -2.39% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB L | $0 | – | -500,000 | -100.0% | -2.39% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -528,244 | -100.0% | -2.87% | – |
| ASND | Exit | ASCENDIS PHARMA A/Ssponsored adr | $0 | – | -700,000 | -100.0% | -3.59% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| JAZZ PHARMACEUTICALS PLC | 8 | Q3 2023 | 7.2% |
| TRAVERE THERAPEUTICS INC | 8 | Q3 2023 | 5.7% |
| IMMUNOVANT INC | 8 | Q3 2023 | 7.2% |
| BICYCLE THERAPEUTICS PLC | 8 | Q3 2023 | 5.2% |
| BEAM THERAPEUTICS INC | 8 | Q3 2023 | 3.9% |
| 4D MOLECULAR THERAPEUTICS IN | 8 | Q3 2023 | 2.9% |
| REPARE THERAPEUTICS INC | 8 | Q3 2023 | 3.1% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 2.2% |
| DYNE THERAPEUTICS INC | 8 | Q3 2023 | 2.2% |
| SILENCE THERAPEUTICS PLC | 8 | Q3 2023 | 1.6% |
View Deep Track Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Orchard Therapeutics plc | March 20, 2023 | 19,125,150 | 10.0% |
| ARDELYX, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2023 | 1,833,437 | 3.8% |
| Aurinia Pharmaceuticals Inc. | February 14, 2023 | 324,238 | 0.2% |
| CHINOOK THERAPEUTICS, INC. | February 14, 2023 | 3,000,000 | 4.7% |
| Forma Therapeutics Holdings, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Global Blood Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| HOOKIPA Pharma Inc. | February 14, 2023 | 1,240,369 | 2.4% |
| KalVista Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Keros Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View Deep Track Capital, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-26 |
| SC 13G | 2024-04-26 |
| SC 13G/A | 2024-04-22 |
| SC 13G | 2024-04-12 |
| SC 13G | 2024-04-05 |
| SC 13G | 2024-03-22 |
| SC 13G | 2024-03-22 |
| SC 13G | 2024-03-22 |
| SC 13G | 2024-03-15 |
| 3 | 2024-03-14 |
View Deep Track Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.